%0 Journal Article
%T Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
%A Jun Li
%A Han Zhang
%A Peng Sun
%A Feng Gu
%J International Journal of Ophthalmology
%D 2013
%I IJO Press
%R 10.3980/j.issn.2222-3959.2013.02.12
%X AIM:To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD). METHODS: Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events. RESULTS:At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72¡À0.23 and 0.73¡À0.22 to 0.47¡À0.14 and 0.45¡À0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71¡À34.72¦Ìm and 352¡À36.9¦Ìm at baseline to 250.86¡À41.51¦Ìm and 243.22¡À41.38¦Ìm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events. CONCLUSION:Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
%K age-related macular degeneration
%K choroidal neovascularization
%K bevacizumab (avastin)
%K ranibizumab (lucentis)
%U http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633755/